妊娠期肝内胆汁淤积症：致力于改善围产期结局
Intrahepatic Cholestasis of Pregnancy: Toward Improving Perinatal Outcome.
作者信息
Saad Antonio F, Pacheco Luis D, Chappell Lucy, Saade George R
机构信息
Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX, 77555-0587, USA.
Division of Surgical Critical Care, Department of Anesthesiology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
出版信息
Reprod Sci. 2022 Nov;29(11):3100-3105. doi: 10.1007/s43032-021-00740-x. Epub 2021 Sep 15.
Intrahepatic cholestasis of pregnancy (ICP) is associated with poor perinatal outcomes in some women such as preterm delivery and fetal demise. Ursodeoxycholic acid (UDCA) is the main therapeutic agent for ICP, but recent evidence failed to show an impact on most perinatal outcomes. Our objective is to summarize the latest evidence in the management of ICP, with a focus on perinatal outcome. We propose a practical approach that combines pharmacotherapy with biochemical and fetal testing, as well as delivery planning.
妊娠期肝内胆汁淤积症（ICP）在一些女性中与不良围产期结局相关，如早产和胎儿死亡。熊去氧胆酸（UDCA）是治疗ICP的主要药物，但最近的证据未能显示其对大多数围产期结局有影响。我们的目的是总结ICP管理方面的最新证据，重点关注围产期结局。我们提出一种将药物治疗与生化和胎儿检测以及分娩计划相结合的实用方法。
Zotero 插件